Liver function and pharmacokinetics of molsidomine and its metabolite 3-morpholinosydnonimine in healthy volunteers
- PMID: 3768083
Liver function and pharmacokinetics of molsidomine and its metabolite 3-morpholinosydnonimine in healthy volunteers
Abstract
Plasma levels of N-carboxy-3-morpholinosydnonimine ethyl ester (molsidomine, Corvaton) and its pharmacologically active metabolite 3-morpholinosydnonimine (SIN-1) were measured in six healthy male and female volunteers after single intravenous and oral dosing of 4 mg molsidomine. Additionally indocyanine green and phenazone (antipyrine) clearances were determined to estimate hepatic blood flow and metabolic liver function in each subject. The pharmacokinetic parameters of molsidomine were similar to already published data in healthy volunteers and patients. The plasma level of SIN-1 formed was always lower than the molsidomine level but obviously reflects the corresponding molsidomine concentration time course in plasma. Indocyanine green plasma clearance was reduced by 15%. after intravenous dosing of 4 mg molsidomine. There was no clear-cut relationship between the plasma clearances of molsidomine and phenazone in these subjects with normal metabolic liver function.
Similar articles
-
The absolute bioavailability and pharmacokinetics of butorphanol nasal spray in patients with hepatic impairment.Clin Pharmacol Ther. 1996 Sep;60(3):283-94. doi: 10.1016/S0009-9236(96)90055-7. Clin Pharmacol Ther. 1996. PMID: 8841151
-
Prediction of the lower esophageal sphincter pressure after oral molsidomine by sydnonimine plasma concentrations.Hepatogastroenterology. 1999 Mar-Apr;46(26):933-7. Hepatogastroenterology. 1999. PMID: 10370642 Clinical Trial.
-
[Molsidomine in chronic heart failure with liver congestion--oral or intravenous therapy?].Med Klin (Munich). 1993 Jan 15;88(1):21-5. Med Klin (Munich). 1993. PMID: 8437528 Clinical Trial. German.
-
1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.Dan Med Bull. 2008 Nov;55(4):186-210. Dan Med Bull. 2008. PMID: 19232159 Review.
-
Quantifying hepatic function in the presence of liver disease with phenazone (antipyrine) and its metabolites.Clin Pharmacokinet. 1991 Jan;20(1):50-65. doi: 10.2165/00003088-199120010-00004. Clin Pharmacokinet. 1991. PMID: 2029802 Review.
Cited by
-
Clinical pharmacokinetics of molsidomine.Clin Pharmacokinet. 1996 May;30(5):372-84. doi: 10.2165/00003088-199630050-00004. Clin Pharmacokinet. 1996. PMID: 8743336
-
Nitric oxide donor, linsidomine chlorhydrate (SIN-1), in the diagnosis and treatment of erectile dysfunction: critical appraisal and review of the literature.Int Urol Nephrol. 1995;27(5):621-8. doi: 10.1007/BF02564750. Int Urol Nephrol. 1995. PMID: 8775048 Review.
-
Pharmacokinetic profile of a novel slow release preparation of molsidomine.Eur J Clin Pharmacol. 1992;43(3):273-6. doi: 10.1007/BF02333022. Eur J Clin Pharmacol. 1992. PMID: 1425891
-
Effects of abdominal hot compresses on indocyanine green elimination--a randomized cross over study in healthy subjects.BMC Gastroenterol. 2007 Jul 10;7:27. doi: 10.1186/1471-230X-7-27. BMC Gastroenterol. 2007. PMID: 17623067 Free PMC article. Clinical Trial.
-
Interaction of antiplatelet drugs in vitro: aspirin, iloprost, and the nitric oxide donors SIN-1 and sodium nitroprusside.Cardiovasc Drugs Ther. 1995 Aug;9(4):619-29. doi: 10.1007/BF00878095. Cardiovasc Drugs Ther. 1995. PMID: 8547213